Correlation Between Clinical Response to Hormone Therapy and Steroid Receptor Content in Prostatic Cancer1
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
CANVAS Trial)
Effectiveness research with Real World Data to support FDA’s regulatory decision making 1. RCT Details This section provides a high-level overview of the RCT that the described real-world evidence study is trying to replicate as closely as possible given the remaining limitations inherent in the healthcare databases. 1.1 Title Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS trial) 1.2 Intended aim(s) To compare canagliflozin to placebo on cardiovascular (CV) events including CV death, heart attack, and stroke in patients with type 2 diabetes mellitus (T2DM), whose diabetes is not well controlled at the beginning of the study and who have a history of CV events or have a high risk for CV events. 1.3 Primary endpoint for replication and RCT finding Major Adverse Cardiovascular Events, Including CV Death, Nonfatal Myocardial Infarction (MI), and Nonfatal Stroke 1.4 Required power for primary endpoint and noninferiority margin (if applicable) With 688 cardiovascular safety events recorded across the trials, there would be at least 90% power, at an alpha level of 0.05, to exclude an upper margin of the 95% confidence interval for the hazard ratio of 1.3. 1.5 Primary trial estimate targeted for replication HR = 0.86 (95% CI 0.75–0.97) comparing canagliflozin to placebo (Neal et al., 2017) 2. Person responsible for implementation of replication in Aetion Ajinkya Pawar, Ph.D. implemented the study design in the Aetion Evidence Platform. S/he is not responsible for the validity of the design and analytic choices. All implementation steps are recorded and the implementation history is archived in the platform. -
A Pharmaceutical Product for Hormone Replacement Therapy Comprising Tibolone Or a Derivative Thereof and Estradiol Or a Derivative Thereof
Europäisches Patentamt *EP001522306A1* (19) European Patent Office Office européen des brevets (11) EP 1 522 306 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 31/567, A61K 31/565, 13.04.2005 Bulletin 2005/15 A61P 15/12 (21) Application number: 03103726.0 (22) Date of filing: 08.10.2003 (84) Designated Contracting States: • Perez, Francisco AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 08970 Sant Joan Despi (Barcelona) (ES) HU IE IT LI LU MC NL PT RO SE SI SK TR • Banado M., Carlos Designated Extension States: 28033 Madrid (ES) AL LT LV MK (74) Representative: Markvardsen, Peter et al (71) Applicant: Liconsa, Liberacion Controlada de Markvardsen Patents, Sustancias Activas, S.A. Patent Department, 08028 Barcelona (ES) P.O. Box 114, Favrholmvaenget 40 (72) Inventors: 3400 Hilleroed (DK) • Palacios, Santiago 28001 Madrid (ES) (54) A pharmaceutical product for hormone replacement therapy comprising tibolone or a derivative thereof and estradiol or a derivative thereof (57) A pharmaceutical product comprising an effec- arate or sequential use in a method for hormone re- tive amount of tibolone or derivative thereof, an effective placement therapy or prevention of hypoestrogenism amount of estradiol or derivative thereof and a pharma- associated clinical symptoms in a human person, in par- ceutically acceptable carrier, wherein the product is pro- ticular wherein the human is a postmenopausal woman. vided as a combined preparation for simultaneous, sep- EP 1 522 306 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 1 522 306 A1 2 Description [0008] The review article of Journal of Steroid Bio- chemistry and Molecular Biology (2001), 76(1-5), FIELD OF THE INVENTION: 231-238 provides a review of some of these compara- tive studies. -
Eligibility Regulations for Transgender Athletes
ELIGIBILITY REGULATIONS FOR TRANSGENDER ATHLETES In the case of confidential queries regarding cases affected by these Transgender Regulations, please contact: WT Medical Manager (email: [email protected]) Table of Contents 1. Introduction ....................................................................................................................... 1 2. Application ........................................................................................................................ 3 3. Eligibility Conditions For Transgender Athletes ................................................................... 5 3a. Eligibility conditions for Transgender male athletes .......................................................... 5 3b. Eligibility conditions for Transgender female athletes ....................................................... 5 3c. Provisions applicable to all Transgender athletes .............................................................. 5 4. Assessment by the Expert Panel ......................................................................................... 7 5. Monitoring/Investigating Compliance ................................................................................ 9 6. Disciplinary Proceedings .................................................................................................... 11 7. Dispute Resolution ............................................................................................................ 12 8. Confidentiality ................................................................................................................. -
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0 -
Cumulative Cross Index to Iarc Monographs
PERSONAL HABITS AND INDOOR COMBUSTIONS volume 100 e A review of humAn cArcinogens This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 29 September-6 October 2009 LYON, FRANCE - 2012 iArc monogrAphs on the evAluAtion of cArcinogenic risks to humAns CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS The volume, page and year of publication are given. References to corrigenda are given in parentheses. A A-α-C .............................................................40, 245 (1986); Suppl. 7, 56 (1987) Acenaphthene ........................................................................92, 35 (2010) Acepyrene ............................................................................92, 35 (2010) Acetaldehyde ........................36, 101 (1985) (corr. 42, 263); Suppl. 7, 77 (1987); 71, 319 (1999) Acetaldehyde associated with the consumption of alcoholic beverages ..............100E, 377 (2012) Acetaldehyde formylmethylhydrazone (see Gyromitrin) Acetamide .................................... 7, 197 (1974); Suppl. 7, 56, 389 (1987); 71, 1211 (1999) Acetaminophen (see Paracetamol) Aciclovir ..............................................................................76, 47 (2000) Acid mists (see Sulfuric acid and other strong inorganic acids, occupational exposures to mists and vapours from) Acridine orange ...................................................16, 145 (1978); Suppl. 7, 56 (1987) Acriflavinium chloride ..............................................13, -
Estradiol for the Mitigation of Adverse Effects of Androgen Deprivation Therapy
248 N Russell et al. Estradiol and androgen 24:8 R297–R313 Review deprivation therapy Estradiol for the mitigation of adverse effects of androgen deprivation therapy Nicholas Russell1,2, Ada Cheung1,2 and Mathis Grossmann1,2 Correspondence should be addressed 1 Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia to N Russell 2 Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia Email [email protected] Abstract Prostate cancer (PCa) is the second most commonly diagnosed cancer in men. Key Words Conventional endocrine treatment for PCa leads to global sex steroid deprivation. f endocrine therapy The ensuing severe hypogonadism is associated with well-documented adverse effects. f prostate Recently, it has become apparent that many of the biological actions attributed to f estrogen androgens in men are in fact not direct, but mediated by estradiol. Available evidence f androgen supports a primary role for estradiol in vasomotor stability, skeletal maturation and f testosterone maintenance, and prevention of fat accumulation. Hence there has been interest in revisiting estradiol as a treatment for PCa. Potential roles for estradiol could be in lieu of conventional androgen deprivation therapy or as low-dose add-back treatment while continuing androgen deprivation therapy. These strategies may limit some of the side Endocrine-Related Cancer Endocrine-Related effects associated with conventional androgen deprivation therapy. However, although available data are reassuring, the potential for cardiovascular risk and pro-carcinogenic Endocrine-Related Cancer effects on PCa via estrogen receptor signalling must be considered. (2017) 24, R297–R313 Introduction Prostate cancer (PCa) is the second most commonly and extragonadal androgen synthesis inhibitors. -
Vastly Extended Drug Release from Poly(Pro-17β-Estradiol)
ARTICLE https://doi.org/10.1038/s41467-019-12835-w OPEN Vastly extended drug release from poly(pro-17β- estradiol) materials facilitates in vitro neurotrophism and neuroprotection Anthony R. D’Amato 1, Devan L. Puhl 1,3, Samuel A.T. Ellman2,3, Bailey Balouch1, Ryan J. Gilbert 1*& Edmund F. Palermo 2* 1234567890():,; Central nervous system (CNS) injuries persist for years, and currently there are no ther- apeutics that can address the complex injury cascade that develops over this time-scale. 17β- estradiol (E2) has broad tropism within the CNS, targeting and inducing beneficial phenotypic changes in myriad cells following injury. To address the unmet need for vastly prolonged E2 release, we report first-generation poly(pro-E2) biomaterial scaffolds that release E2 at nanomolar concentrations over the course of 1–10 years via slow hydrolysis in vitro. As a result of their finely tuned properties, these scaffolds demonstrate the ability to promote and guide neurite extension ex vivo and protect neurons from oxidative stress in vitro. The design and testing of these materials reported herein demonstrate the first step towards next- generation implantable biomaterials with prolonged release and excellent regenerative potential. 1 Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110 8th St., Troy, NY 12180, USA. 2 Materials Science and Engineering, Rensselaer Polytechnic Institute, 110 8th St., Troy, NY 12180, USA. 3These authors contributed equally: Devan L. Puhl, Samuel A.T. Ellman. *email: [email protected]; [email protected] NATURE COMMUNICATIONS | (2019) 10:4830 | https://doi.org/10.1038/s41467-019-12835-w | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12835-w njuries to the Central Nervous System (CNS), including Spinal thereby enabling faster regeneration along the orientation of the ICord Injury (SCI) and Traumatic Brian Injury (TBI), present fibers33. -
Controversies in the Management of Advanced Prostate Cancer
British Journal of Cancer (1999) 79(1), 146–155 © 1999 Cancer Research Campaign Controversies in the management of advanced prostate cancer CJ Tyrrell Oncology Research Unit, Derriford Hospital, Plymouth, UK Summary For advanced prostate cancer, the main hormone treatment against which other treatments are assessed is surgical castration. It is simple, safe and effective, however it is not acceptable to all patients. Medical castration by means of luteinizing hormone-releasing hormone (LH-RH) analogues such as goserelin acetate provides an alternative to surgical castration. Diethylstilboestrol, previously the only non-surgical alternative to orchidectomy, is no longer routinely used. Castration reduces serum testosterone by around 90%, but does not affect androgen biosynthesis in the adrenal glands. Addition of an anti-androgen to medical or surgical castration blocks the effect of remaining testosterone on prostate cells and is termed combined androgen blockade (CAB). CAB has now been compared with castration alone (medical and surgical) in numerous clinical trials. Some trials show advantage of CAB over castration, whereas others report no significant difference. The author favours the view that CAB has an advantage over castration. No study has reported that CAB is less effective than castration. Of the anti-androgens which are available for use in CAB, bicalutamide may be associated with a lower incidence of side-effects compared with the other non-steroidal anti-androgens and, in common with nilutamide, has the advantage of once-daily dosing. Only one study has compared anti-androgens within CAB: bicalutamide plus LH-RH analogue and flutamide plus LH-RH analogue. At 160- week follow-up, the groups were equivalent in terms of survival and time to progression. -
Parenteral Estrogen Versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No
Scandinavian Journal of Urology and Nephrology ISSN: 0036-5599 (Print) 1651-2065 (Online) Journal homepage: https://www.tandfonline.com/loi/isju19 Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No. 5 Per Olov Hedlund, Martti Ala-Opas, Einar Brekkan, Jan Erik Damber, Lena Damber, Inger Hagerman, Svein Haukaas, Peter Henriksson, Peter Iversen, Åke Pousette, Finn Rasmussen, Jaakko Salo, Sigmund Vaage & Eberhard Varenhorst To cite this article: Per Olov Hedlund, Martti Ala-Opas, Einar Brekkan, Jan Erik Damber, Lena Damber, Inger Hagerman, Svein Haukaas, Peter Henriksson, Peter Iversen, Åke Pousette, Finn Rasmussen, Jaakko Salo, Sigmund Vaage & Eberhard Varenhorst (2002) Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No. 5, Scandinavian Journal of Urology and Nephrology, 36:6, 405-413, DOI: 10.1080/003655902762467549 To link to this article: https://doi.org/10.1080/003655902762467549 Published online: 09 Jul 2009. Submit your article to this journal Article views: 72 Citing articles: 33 View citing articles Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=isju20 ORIGINAL ARTICLE Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer ScandinavianProstatic Cancer Group(SPCG) Study No. 5 Per Olov Hedlund, -
Centre for Reviews and Dissemination Parenteral Oestrogens for Prostate
Centre for Reviews and Dissemination A Systematic Review of Parenteral Oestrogens for Prostate Cancer Parenteral Oestrogens for Prostate Cancer: A Systematic Review of Clinical Effectiveness and Dose Response 33 Promoting the use of research based knowledge REPORT 33 CRD Parenteral oestrogens for prostate cancer: A systematic review of clinical effectiveness and dose response Michael Emmans Dean2 Gill Norman1 Zoé Hodges6 Gill Ritchie3 Kate Light1 Alison Eastwood1 Ruth Langley4 Matthew Sydes4 Mahesh Parmar4 Paul Abel5 1 Centre for Reviews and Dissemination, University of York, York YO10 5DD 2 Department of Health Sciences, University of York, York YO10 5DD 3National Collaborating Centre for Primary Care, Frazer House, 32-38 Leman Street, London, E1 8EW 4MRC Clinical Trials Unit, 222 Euston Road, London 5Imperial College, London, W12 0NN 6 Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, WC1B 3RE September 2006 © 2006 Centre for Reviews and Dissemination, University of York ISBN 1 900640 37 6 This report can be ordered from: Publications Office, Centre for Reviews and Dissemination, University of York, York YO10 5DD. Telephone 01904 321458; Facsimile: 01904 321035: email: [email protected] Price £12.50 The Centre for Reviews and Dissemination is funded by the NHS Executive and the Health Departments of Wales and Northern Ireland. The views expressed in this publication are those of the authors and not necessarily those of the NHS Executive or the Health Departments of Wales or Northern Ireland. Printed by York Publishing Services Ltd. ii CENTRE FOR REVIEWS AND DISSEMINATION The Centre for Reviews and Dissemination (CRD) is a facility commissioned by the NHS Research and Development Division. -
Cardiovascular Toxicities of Systemic Treatments of Prostate Cancer
CORRESPONDENCE LINK TO ORIGINAL ARTICLE LINK TO AUTHOR’S REPLY knowledge to participate in choosing favoured therapies. Sharing decision mak- Cardiovascular toxicities of systemic ing will offer opportunities for patients, enabling them, together with their families treatments of prostate cancer: and friends, to engage with personalized medicine, but this process requires thorough oestrogen to the rescue? acquisition of comprehensive, up-to-date, relevant background data. Syed Imran A. Shah, Hannah C. P. Wilson & Paul D. Abel Syed Imran A. Shah is at the Biochemistry Department at Central Park Medical College, Central Park Housing Scheme, 31 km Ferozepur Road, Kahna Nau, Lahore, In their Review (Cardiovascular toxicities By the early 1990s, reports of paren- Punjab, Pakistan. of systemic treatments of prostate cancer. teral oestrogen administration for prostate Hannah C. P. Wilson is at Imperial NHS Trust, 1 Nat. Rev. Urol. 14, 230–243 (2017)) Veccia cancer (injection or skin patch) had been The Bays, South Wharf Road, St Mary’s Hospital, et al. offer useful insight into current encouraging. A Scandinavian research team London W2 1NY. knowledge concerning cardiovascular com- recruited 915 men into a two-arm study of Paul D. Abel is at South Kensington Campus, plications of oral oestrogen, androgen dep- luteinising-hormone-releasing hormone London, SW7 2AZ, UK . rivation therapy (ADT), and prostate cancer. (LHRH) agonist plus antiandrogens ver- Correspondence to: S.I.A.S. However, we do not share the confidence and sus intramuscular polyestradiol phosphate [email protected] strength of their assertion that “oestrogens (a synthetic oestrogen). Overall prostate can- doi:10.1038/nrurol.2017.126 are no longer used in patients with prostate cer mortality was equivalent between groups, Published online 8 Aug 2017 cancer owing to the severity of their adverse but cardiovascular morbidity was either events, which include thromboembolic and not reported or slightly increased in the 1. -
Parenteral Oestrogen in the Treatment of Prostate Cancer: a Systematic Review
British Journal of Cancer (2008) 98, 697 – 707 & 2008 Cancer Research UK All rights reserved 0007 – 0920/08 $30.00 www.bjcancer.com Parenteral oestrogen in the treatment of prostate cancer: a systematic review G Norman1, ME Dean1, RE Langley2, ZC Hodges1, G Ritchie1, MKB Parmar2, MR Sydes2, P Abel3 *,1 and AJ Eastwood 1 2 Centre for Reviews and Dissemination, University of York, York YO10 5DD, UK; Cancer Group, MRC Clinical Trials Unit, 222 Euston Road, London 3 NW1 2DA, UK; Hammersmith Campus, Department of Surgery, Imperial College Faculty of Medicine, London W12 0NN, UK The objectives of this study were to assess the effectiveness and safety of parenteral oestrogen in the treatment of prostate cancer, Clinical Studies and to examine any dose relationship. A systematic review was undertaken. Electronic databases, published paper and internet resources were searched to locate published and unpublished studies with no restriction by language or publication date. Studies included were randomised controlled trials of parenteral oestrogen in patients with prostate cancer; other study designs were also included to examine dose–response. Study selection, appraisal, data extraction and quality assessment were performed by one reviewer and independently checked by another. Twenty trials were included in the review. The trials differed with regard to the included patients, formulation and dose of parenteral oestrogen, comparator used, outcome measures reported and the duration of follow-up. The results provide no evidence to suggest that parenteral oestrogen, in doses sufficient to produce castrate levels of testosterone, is less effective than luteinising hormone-releasing hormone (LHRH) or orchidectomy in controlling prostate cancer, or that it is consistently associated with an increase in cardiovascular mortality.